IceCure Medical Reports Q1 2025 Revenue Decline by 2% with Gross Margin Decrease to 30%

Reuters
28 May
IceCure Medical Reports Q1 2025 Revenue Decline by 2% with Gross Margin Decrease to 30%

IceCure Medical Ltd. has reported its financial results for the first quarter ending March 31, 2025. The company's revenue from sales of ProSense® systems and disposable probes was $725,000, reflecting a 2% decrease from $743,000 in the same period in 2024. This reduction was mainly due to a decline in sales in Asia, although this was partially offset by increases in Europe and North America. Gross profit for the quarter was $218,000, down from $269,000 in the previous year, with a gross margin of 30% compared to 36% in 2024. This decrease was attributed to the slight decline in revenue and changes in product mix. Research and development expenses decreased by 15% to $1.664 million, primarily due to reduced development costs for the XSense™ System following its FDA authorization in June 2024, along with lower clinical and regulatory costs after concluding the ICE3 study in March 2024. Conversely, sales and marketing expenses rose by 24% to $1.289 million as the company ramped up global marketing efforts to support growing sales. IceCure Medical has also delivered a proposed post-market study plan to the U.S. FDA ahead of its marketing authorization decision for ProSense® in women aged 70+ with early-stage low-risk breast cancer. The company continues to witness rising interest for ProSense® in North America. Looking forward, the company does not anticipate a material change in revenues until after the FDA's marketing authorization decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-048020), on May 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10